<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04784013</url>
  </required_header>
  <id_info>
    <org_study_id>2800</org_study_id>
    <nct_id>NCT04784013</nct_id>
  </id_info>
  <brief_title>Very High Power Ablation in Patients With Atrial Fibrillation Scheduled for a First Pulmonary Vein Isolation</brief_title>
  <acronym>POWER-PLUS</acronym>
  <official_title>Very High Power Ablation in Patients With Atrial Fibrillation Scheduled for a First Pulmonary Vein Isolation: the POWER-PLUS Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AZ Sint-Jan AV</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AZ Sint-Jan AV</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective, randomized, controlled, unblinded, multicenter study aims at comparing&#xD;
      procedural time between conventional CLOSE-guided pulmonary vein isolation (PVI) (35W/50W)&#xD;
      versus very high power radiofrequency delivery (90W) in atrial fibrillation patients&#xD;
      scheduled for a first PVI.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 24, 2021</start_date>
  <completion_date type="Anticipated">May 31, 2022</completion_date>
  <primary_completion_date type="Actual">October 22, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Procedural time</measure>
    <time_frame>Procedure (At time of ablation)</time_frame>
    <description>Comparison of the procedural time (in minutes) between groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Single procedure atrial tachyarrhythmia freedom between months 4, 5 and 6 after the index ablation</measure>
    <time_frame>Months 4-6 after ablation</time_frame>
    <description>Atrial tachyarrhythmia will be monitored by Holter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiofrequency (RF) ablation time</measure>
    <time_frame>Procedure (At time of ablation)</time_frame>
    <description>Comparison of the RF ablation time (in seconds) between groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fluoroscopy dose</measure>
    <time_frame>Procedure (At time of ablation)</time_frame>
    <description>Comparison of the fluoroscopy dose (Gy cm²) between groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>First pass isolation rate</measure>
    <time_frame>Procedure (At time of ablation)</time_frame>
    <description>Reconnection of the veins after adenosine injection or waiting time</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">182</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Conventional group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>90W-group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Conventional CLOSE-guided pulmonary vein isolation</intervention_name>
    <description>Point-by-point RF delivery will be performed aiming for a contiguous circle enclosing the veins. RF will be delivered in a temperature and flow-controlled mode (QMODE, target temperature 45°C, low flow temperature 40°C, cut-off temperature 50°C) with a power of 35W(posterior)/50W(anterior) (irrigation flow at 4-15ml/min). RF will be delivered until an ablation index (AI) of ≥400 at the posterior wall/roof/south pole and ≥550 at the anterior wall.</description>
    <arm_group_label>Conventional group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>High power short duration pulmonary vein isolation</intervention_name>
    <description>Point-by-point RF delivery will be performed aiming for a contiguous circle enclosing the veins. RF will be delivered in temperature-controlled mode (QMode+, target temperature 55°C, cut-off temperature 65°C) with a power of 90W (irrigation flow at 2-8ml/min). RF will be delivered for 4 sec at both the posterior and anterior wall.</description>
    <arm_group_label>90W-group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients older than 18 years&#xD;
&#xD;
          -  Patients scheduled for a first PVI only for paroxysmal atrial fibrillation (AF)&#xD;
             (self-terminating or &lt;7days) or persistent AF (persistent AF is defined as having an&#xD;
             AF episode &gt;7d); (patients with paroxysmal AF or short-standing persistent AF&#xD;
             presenting with flutter, who are in need of a cavotricuspid isthmus ablation, are&#xD;
             allowed to participate in this trial)&#xD;
&#xD;
          -  Patients willing to sign informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with long-standing persistent AF (long-standing persistent AF is defined as&#xD;
             having an AF episode &gt;1yr)&#xD;
&#xD;
          -  Previous ablation for AF&#xD;
&#xD;
          -  Left atrium antero-posterior diameter &gt;50 mm (parasternal long axis view, PLAX)&#xD;
&#xD;
          -  AF secondary to electrolyte imbalance, thyroid disease, or reversible or non-cardiac&#xD;
             cause&#xD;
&#xD;
          -  Left atrial appendage (LAA) thrombus. LAA thrombus can be determined by preprocedural&#xD;
             imaging: CT, transesophageal echocardiography or MRI.&#xD;
&#xD;
          -  Left ventricular ejection fraction &lt;35%.&#xD;
&#xD;
          -  Cardiac surgery within the previous 90 days.&#xD;
&#xD;
          -  Expecting cardiac transplantation or other cardiac surgery within 180 days.&#xD;
&#xD;
          -  Coronary percutaneous transluminal coronary angioplasty/stenting within the previous&#xD;
             90 days or myocardial infarction within the previous 60 days.&#xD;
&#xD;
          -  Documented history of a thromboembolic event within the previous 90 days.&#xD;
&#xD;
          -  Diagnosed atrial myxoma.&#xD;
&#xD;
          -  Significant restrictive, constrictive, or chronic obstructive pulmonary disease with&#xD;
             chronic symptoms.&#xD;
&#xD;
          -  Significant congenital anomaly or medical problem that in the opinion of the&#xD;
             investigator would preclude enrollment&#xD;
&#xD;
          -  Women who are pregnant or who plan to become pregnant during the study.&#xD;
&#xD;
          -  Acute illness or active infection at time of index procedure&#xD;
&#xD;
          -  Advanced renal insufficiency&#xD;
&#xD;
          -  Unstable angina.&#xD;
&#xD;
          -  History of blood clotting or bleeding abnormalities.&#xD;
&#xD;
          -  Contraindication to anticoagulation.&#xD;
&#xD;
          -  Life expectancy less than 1 year.&#xD;
&#xD;
          -  Presence of a condition that precludes vascular access.&#xD;
&#xD;
          -  Unwilling or unable to provide informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mattias Duytschaever, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AZ Sint-Jan AV</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University Hospital Graz</name>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Sint-Jan Brugge-Oostende AV</name>
      <address>
        <city>Brugge</city>
        <state>Please Select</state>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMC Leiden</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Luzerner Kantonsspital</name>
      <address>
        <city>Luzern</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Netherlands</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>March 3, 2021</study_first_submitted>
  <study_first_submitted_qc>March 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 5, 2021</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>AZ Sint-Jan AV</investigator_affiliation>
    <investigator_full_name>Prof. Dr. Mattias Duytschaever</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

